Home Capital Broker's Calls

Ang Peng Tiam's suspension to remain key near-term overhang on TalkMed: CIMB

Michelle Zhu
Michelle Zhu1/8/2018 11:30 AM GMT+08  • 2 min read
Ang Peng Tiam's suspension to remain key near-term overhang on TalkMed: CIMB
SINGAPORE (Jan 8): CIMB is maintaining its “hold” call on TalkMed Group with a lower target price of 68 cents from 92 cents previously, after cutting FY17-19F earnings per share (EPS) estimates by 18-21% to factor anticipated earnings losses from the
Font Resizer
Share to WhatsappShare to FacebookShare to LinkedInMore Share
Scroll to top
Follow us on Facebook and join our Telegram channel for the latest updates.

SINGAPORE (Jan 8): CIMB is maintaining its “hold” call on TalkMed Group with a lower target price of 68 cents from 92 cents previously, after cutting FY17-19F earnings per share (EPS) estimates by 18-21% to factor anticipated earnings losses from the recent suspension of the group’s key doctor and CEO, Ang Peng Tiam, on the grounds of professional misconduct in 2010.


See: TalkMed CEO Ang Peng Tiam handed 8-month suspension for professional misconduct in 2010

Following the announcement of Ang’s eight-month suspension starting from end-July in 2017, TalkMed posted a 17.2% decline in 3Q earnings to $7.1 million from $8.6 million a year ago, and said it expected Ang’s suspension to have a material impact on its revenue and earnings going forward.

For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
×
Loading next article...
The Edge Singapore
Download The Edge Singapore App
Google playApple store play
Keep updated
Follow our social media
Subscribe to The Edge Singapore
Get credible investing ideas from our in-depth stock analysis, interviews with key executives, corporate movements coverage and their impact on the market.
© 2022 The Edge Publishing Pte Ltd. All rights reserved.
Unlock unlimited access to premium articles with less than $9 per month. Subscribe Now